13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001674546
Total reported value
$4.8B
$4.8B
148 檔
32.0%
During the Q3 2025 filing period, Bellevue Group AG (CIK: 0001674546) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $4.8B across 148 reported positions.
In Q3 2025, Bellevue Group AG adopted a defensive or profit-taking posture, trimming 77 positions and completely liquidating 19 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 8.49% | -1.63% | -20.49% | |
| 2 | ARGX | Argenx Se - Adr | Stock-Healthcare | 8.37% | +0.44% | -4.33% | |
| 3 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 5.41% | +0.56% | +21.72% | |
| 4 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 5.14% | +0.08% | -3.13% | |
| 5 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 4.23% | -1.84% | -33.98% | |
| 6 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 4.12% | -1.20% | +14.54% | |
| 7 | ABT | Abbott Laboratories | Stock-Healthcare | 4.11% | -1.00% | -5.46% | |
| 8 | SYK | Stryker CORP | Stock-Healthcare | 3.46% | +0.08% | -15.70% | |
| 9 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.37% | -1.39% | -5.97% | |
| 10 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 3.24% | -1.01% | -7.95% | |
| 11 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 3.10% | — | +3.47% | |
| 12 | INCY | Incyte CORP | Stock-Healthcare | 2.54% | — | -8.26% | |
| 13 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.51% | -1.36% | +10.09% | |
| 14 | AKRO | Akero Therapeutics Inc | Stock-Other | 2.36% | — | +20.35% | |
| 15 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 2.11% | -0.15% | +14.54% | |
| 16 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 1.95% | — | — | |
| 17 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.91% | +0.03% | +7.56% | |
| 18 | MDT | Medtronic plc | Stock-Healthcare | 1.50% | -0.33% | -17.50% | |
| 19 | BEAM | Beam Therapeutics Inc | Stock-Other | 1.46% | — | — | |
| 20 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.45% | -0.19% | +0.85% | |
| 21 | PODD | Insulet CORP | Stock-Healthcare | 1.36% | -0.41% | -3.20% | |
| 22 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.22% | +0.35% | +19.51% | |
| 23 | BDX | Becton Dickinson And Co | Stock-Healthcare | 1.15% | -0.11% | -6.26% | |
| 24 | DXCM | Dexcom Inc | Stock-Healthcare | 1.10% | -0.01% | -8.68% | |
| 25 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.07% | +0.09% | -6.48% | |
| 26 | IDXX | Idexx Laboratories Inc | Stock-Healthcare | 1.02% | -0.51% | +0.05% | |
| 27 | RMD | Resmed Inc | Stock-Healthcare | 0.94% | -0.24% | -0.58% | |
| 28 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.94% | -1.15% | EXIT | |
| 29 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.91% | +0.59% | +1.39% | |
| 30 | BHVN | Biohaven Ltd. | Stock-Other | 0.87% | — | — | |
| 31 | ABBV | Abbvie Inc | Stock-Healthcare | 0.82% | -0.27% | +7.02% | |
| 32 | PEN | Penumbra Inc | Stock-Healthcare | 0.77% | -0.10% | EXIT | |
| 33 | CI | THE Cigna Group | Stock-Healthcare | 0.73% | -0.23% | +10.63% | |
| 34 | GEHC | GE Healthcare Technology | Stock-Healthcare | 0.72% | -0.37% | -10.17% | |
| 35 | ELV | Elevance Health Inc | Stock-Healthcare | 0.70% | +0.09% | +27.93% | |
| 36 | DHR | Danaher CORP | Stock-Healthcare | 0.68% | -0.33% | +19.78% | |
| 37 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.64% | +0.01% | -0.99% | |
| 38 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.62% | — | EXIT | |
| 39 | MCK | Mckesson CORP | Stock-Healthcare | 0.61% | -0.31% | -6.20% | |
| 40 | STE | STERIS plc | Stock-Healthcare | 0.61% | -0.09% | +7.49% | |
| 41 | VEEV | Veeva Systems Inc-class A | Stock-Healthcare | 0.60% | -0.02% | -13.96% | |
| 42 | HCA | Hca Healthcare Inc | Stock-Healthcare | 0.58% | -0.24% | -33.81% | |
| 43 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 0.50% | -0.10% | -8.41% | |
| 44 | COO | Cooper Cos Inc/the | Stock-Healthcare | 0.42% | -0.16% | -17.92% | |
| 45 | HUM | Humana Inc | Stock-Healthcare | 0.41% | +0.22% | +55.34% | |
| 46 | GMED | Globus Medical Inc - A | Stock-Healthcare | 0.39% | -0.27% | -1.65% | |
| 47 | ALGN | Align Technology Inc | Stock-Healthcare | 0.38% | -0.07% | -4.05% | |
| 48 | MOH | Molina Healthcare Inc | Stock-Healthcare | 0.36% | +0.13% | NEW | |
| 49 | HO1 | Hologic Inc | Stock-Other | 0.35% | — | — | |
| 50 | MGNX | Macrogenics Inc | Stock-Other | 0.35% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | IONS | Ionis Pharmaceuticals Inc | +3.2% | -20.49% | Trim |
| 2 | RVMD | Revolution Medicines Inc | +1.9% | +21.72% | Add |
| 3 | IMCR | Immunocore Holdings Plc-adr | +1.3% | +14.54% | Add |
| 4 | AKRO | Akero Therapeutics Inc | +1.2% | +20.35% | Add |
| 5 | AGIO | Agios Pharmaceuticals Inc | +0.8% | +3.47% | Add |
| 6 | SRRK | Scholar Rock Holding CORP | +0.7% | +10.09% | Add |
| 7 | ARGX | Argenx Se - Adr | +0.7% | -4.33% | Trim |
| 8 | CLDX | Celldex Therapeutics Inc | +0.7% | +7.56% | Add |
| 9 | NBIX | Neurocrine Biosciences Inc | +0.6% | -3.13% | Trim |
| 10 | RLAY | Relay Therapeutics Inc | +0.5% | +1.39% | Add |
| 11 | BEAM | Beam Therapeutics Inc | +0.4% | — | Add |
| 12 | TMO | Thermo Fisher Scientific Inc | +0.4% | -6.48% | Add |
| 13 | ELV | Elevance Health Inc | +0.3% | +27.93% | Add |
| 14 | IDXX | Idexx Laboratories Inc | +0.3% | +0.05% | Trim |
| 15 | EWTX | Edgewise Therapeutics Inc | +0.2% | — | Add |
| 16 | HUM | Humana Inc | +0.2% | +55.34% | Add |
| 17 | ABBV | Abbvie Inc | +0.2% | +7.02% | Add |
| 18 | TEVA | Teva Pharmaceutical-sp Adr | +0.2% | +0.61% | Add |
| 19 | MCK | Mckesson CORP | +0.2% | -6.20% | Add |
| 20 | RMD | Resmed Inc | +0.1% | -0.58% | Trim |
| 21 | DHR | Danaher CORP | +0.1% | +19.78% | Add |
| 22 | ANNX | Annexon Inc | +0.1% | — | Unchanged |
| 23 | HCA | Hca Healthcare Inc | +0.1% | -33.81% | Add |
| 24 | GPCR | Structure Therapeutics Inc | +0.1% | -9.37% | Add |
| 25 | CNC | Centene CORP | +0.1% | +102.39% | Add |
| 26 | ASND | Ascendis Pharma A/S | +0.1% | -13.09% | Add |
| 27 | MGNX | Macrogenics Inc | +0.1% | — | Trim |
| 28 | STE | STERIS plc | +0.1% | +7.49% | Add |
| 29 | BNTX | Biontech Se-adr | +0.1% | -3.09% | Add |
| 30 | JNJ | Johnson & Johnson | 0% | +9.67% | Add |
| 31 | MASI* | Masimo CORP | 0% | +8.14% | Add |
| 32 | CVS | Cvs Health CORP | 0% | +70.12% | Add |
| 33 | TXG | 10x Genomics Inc-class A | 0% | -3.95% | Add |
| 34 | ONC | Beone Medicines Ltd-adr | 0% | -12.66% | Trim |
| 35 | BTSG | Brightspring Health Services | 0% | -0.62% | Trim |
| 36 | VEEV | Veeva Systems Inc-class A | 0% | -13.96% | Trim |
| 37 | TMDX | Transmedics Group Inc | 0% | -10.38% | Trim |
| 38 | HO1 | Hologic Inc | 0% | — | Unchanged |
| 39 | MLYS | Mineralys Therapeutics Inc | 0% | +71.03% | Add |
| 40 | MDGL | Madrigal Pharmaceuticals Inc | 0% | +117.55% | Add |
| 41 | BBIO | Bridgebio Pharma Inc | 0% | +95.73% | Add |
| 42 | BMY | Bristol-myers Squibb Co | 0% | +28.07% | Add |
| 43 | BIIB | Biogen Inc | 0% | +948.01% | Add |
| 44 | PTGX | Protagonist Therapeutics Inc | 0% | +5.70% | Add |
| 45 | BBNX | Beta Bionics Inc | 0% | -3.80% | Trim |
| 46 | TEM | Tempus Ai Inc-cl A | 0% | +2015.19% | Add |
| 47 | GRMN | Garmin Ltd. | 0% | +138.94% | Add |
| 48 | AMZN | Amazon.com Inc | 0% | +57.57% | Add |
| 49 | MLTX | Moonlake Immunotherapeutics | 0% | +1068.40% | Add |
| 50 | GOOGL | Alphabet Inc-cl A | 0% | -25.38% | Trim |
According to official SEC Form 13F filings, Bellevue Group AG reported a total U.S. public equity portfolio value of $4.8B across 148 disclosed positions in Q3 2025.
During Q3 2025, Bellevue Group AG's top holdings by market value included IONS (8.5%)、ARGX (8.4%)、RVMD (5.4%). The largest single position, IONS, represented 8.5% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including IONS, ARGX, RVMD) accounted for 32.0% of total reported equity market value during Q3 2025.
Top New Position Initiated
RNAGBP
市值: $93.8M
Top Position Liquidated / Trimmed
BRKR
前期市值: $14.0M
In Q3 2025, Bellevue Group AG made 157 total portfolio adjustments, initiating 19 new buys, adding to 42 positions, trimming 77 holdings, and fully liquidating 19 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.